
KZR
Healthcare · Biotechnology · $53.9M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2026
EPS trend, 90 days to now · +27.5% over 90 days · 30-day revisions 1 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Mar 30, 2026 | Time not confirmed | -1.31 | -1.05 | +19.6% |
| Nov 12, 2025 | Time not confirmed | -0.26 | -1.53 | -488.5% |
| Aug 13, 2025 | Time not confirmed | -0.28 | -1.87 | -567.9% |
| Jun 18, 2025 | After the close | -2.65 | -2.00 | +24.5% |
| Mar 12, 2025 | Before the open | -2.76 | -3.00 | -8.7% |
| Nov 13, 2024 | Before the open | -3.15 | -2.78 | +11.7% |
| Aug 13, 2024 | After the close | -0.32 | -0.27 | +15.6% |
| May 9, 2024 | After the close | -0.33 | -0.30 | +9.1% |
| Mar 14, 2024 | After the close | -0.38 | -0.44 | -15.8% |
| Nov 13, 2023 | After the close | -0.35 | -0.32 | +8.6% |
| Aug 10, 2023 | After the close | -0.32 | -0.34 | -6.3% |
| May 11, 2023 | After the close | -0.29 | -0.31 | -6.9% |
| Mar 14, 2023 | After the close | -0.28 |
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase…
| -0.25 |
| +10.7% |
| Nov 10, 2022 | After the close | -0.27 | -0.25 | +7.4% |
| Aug 11, 2022 | After the close | -0.27 | -0.25 | +7.4% |
| May 12, 2022 | After the close | -0.28 | -0.26 | +7.1% |
| Mar 17, 2022 | After the close | -0.30 | -0.25 | +16.7% |
| Nov 9, 2021 | After the close | -0.26 | -0.28 | -7.7% |
| Aug 12, 2021 | After the close | -0.26 | -0.25 | +3.8% |
| May 12, 2021 | After the close | -0.24 | -0.25 | -4.2% |
| Mar 11, 2021 | After the close | -0.23 | -0.22 | +4.3% |
| Nov 5, 2020 | After the close | -0.21 | -0.23 | -9.5% |
| Aug 5, 2020 | After the close | -0.26 | -0.22 | +15.4% |
| May 7, 2020 | After the close | -0.37 | -0.30 | +18.9% |
| Mar 12, 2020 | After the close | -0.54 | -0.50 | +7.4% |
| Nov 6, 2019 | After the close | -0.51 | -0.48 | +5.9% |
| Aug 7, 2019 | After the close | -0.48 | -0.46 | +4.2% |
| May 7, 2019 | After the close | -0.40 | -0.40 | 0.0% |
| Mar 26, 2019 | Before the open | -0.44 | -0.30 | +31.8% |
| Nov 8, 2018 | Before the open | -0.48 | -0.30 | +37.5% |
| Aug 9, 2018 | After the close | -0.52 | -3.31 | -536.5% |
| May 24, 2018 | After the close | 0.00 | -4.67 | — |
| Mar 21, 2018 | Time not confirmed | — | 0.02 | — |